Literature DB >> 23220408

β-defensin-3 negatively regulates TLR4-HMGB1 axis mediated HLA-G expression in IL-1β treated glioma cells.

Piyushi Gupta1, Sadashib Ghosh, Ashwat Nagarajan, Veer Singh Mehta, Ellora Sen.   

Abstract

The non-classical HLA class I antigen HLA-G contributes to immune escape mechanisms in glioblastoma multiforme (GBM). We have previously shown that IL-1β-HIF-1α axis connects inflammatory and oncogenic pathways in GBM. In this study, we investigated the role of IL-1β induced inflammation in regulating HLA-G expression. IL-1β increased HLA-G and Toll like receptor 4 (TLR4) expression in a HIF-1α dependent manner. Inhibition of TLR4 signaling abrogated IL-1β induced HLA-G. IL-1β increased HMGB1 expression and its interaction with TLR4. Inhibition of HMGB1 inhibited TLR4 and vice versa suggesting the existence of HMGB1-TLR4 axis in glioma cells. Interestingly, HMGB1 inhibition prevented IL-1β induced HLA-G expression. Elevated levels of HMGB1 and β-defensin 3 were observed in GBM tumors. Importantly, β-defensin-3 prevented IL-1β induced HLA-G, TLR4, HMGB1 expression and release of pro-inflammatory mediators. Our studies indicate that β-defensin-3 abrogates IL-1β induced HLA-G expression by negatively affecting key molecules associated with its regulation.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23220408     DOI: 10.1016/j.cellsig.2012.12.001

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  16 in total

1.  MicroRNA-218 modulates activities of glioma cells by targeting HMGB1.

Authors:  Jianjun Gu; Rong Xu; Yaxing Li; Jianhe Zhang; Shousen Wang
Journal:  Am J Transl Res       Date:  2016-09-15       Impact factor: 4.060

2.  Up-regulation of LINC00665 contributes to the progression of glioma and correlates with its MRI characteristics.

Authors:  Wangsheng Chen; Lan Hong; Changlong Hou; Genlin Zong; Jianhua Zhang
Journal:  Am J Transl Res       Date:  2022-05-15       Impact factor: 3.940

Review 3.  Pivotal role of high-mobility group box 1 (HMGB1) signaling pathways in glioma development and progression.

Authors:  Efthalia Angelopoulou; Christina Piperi; Christos Adamopoulos; Athanasios G Papavassiliou
Journal:  J Mol Med (Berl)       Date:  2016-06-04       Impact factor: 4.599

4.  An integrated transcriptomic and computational analysis for biomarker identification in human glioma.

Authors:  Wenli Xing; Chun Zeng
Journal:  Tumour Biol       Date:  2015-12-14

5.  Clinical and prognostic significance of high-mobility group box-1 in human gliomas.

Authors:  Xin-Jun Wang; Shao-Long Zhou; Xu-Dong Fu; Yan-Yan Zhang; Bo Liang; Ji-Xin Shou; Jian-Ye Wang; Jian Ma
Journal:  Exp Ther Med       Date:  2014-11-25       Impact factor: 2.447

Review 6.  Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma.

Authors:  Shuanglin Deng; Shan Zhu; Yuan Qiao; Yong-Jun Liu; Wei Chen; Gang Zhao; Jingtao Chen
Journal:  Protein Cell       Date:  2014-11-21       Impact factor: 14.870

Review 7.  Hypoxic Modulation of HLA-G Expression through the Metabolic Sensor HIF-1 in Human Cancer Cells.

Authors:  Marica Garziera; Lucia Scarabel; Giuseppe Toffoli
Journal:  J Immunol Res       Date:  2017-07-11       Impact factor: 4.818

8.  High expression of the HMGB1-TLR4 axis and its downstream signaling factors in patients with Parkinson's disease and the relationship of pathological staging.

Authors:  Yi Yang; Chenyang Han; Li Guo; Qiaobin Guan
Journal:  Brain Behav       Date:  2018-03-25       Impact factor: 2.708

9.  Plasmatic membrane toll-like receptor expressions in human astrocytomas.

Authors:  Isabele Fattori Moretti; Daiane Gil Franco; Thais Fernanda de Almeida Galatro; Sueli Mieko Oba-Shinjo; Suely Kazue Nagahashi Marie
Journal:  PLoS One       Date:  2018-06-18       Impact factor: 3.240

Review 10.  Immunomodulatory properties of HLA-G in infectious diseases.

Authors:  Laurence Amiot; Nicolas Vu; Michel Samson
Journal:  J Immunol Res       Date:  2014-04-15       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.